問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Principal Investigator

Principal Investigator


National Taiwan University Hospital (在職)

Division of Endocrinology

Division of Cardiovascular Diseases

Division of General Internal Medicine

Far Eastern Memorial Hospital (在職)

Division of General Internal Medicine

Division of Endocrinology

更新時間：2025-12-16

王景淵 (王治元)WANG, CHIH-YUAN
  • Principal Investigator
  • Clinical Trial Experience (year) 23 years 3 個月

  • ejchung@gmail.com

Recruiting Trial

9Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

王景淵 (王治元)

List

33Cases

2014-12-30 - 2019-12-31

Phase III

A Long-Term Outcomes Study to Assess STatin Residual Risk Reduction with EpaNova in HiGh Cardiovascular Risk PatienTs with Hypertriglyceridemia (STRENGTH)

  • Condition/Disease

    major adverse cardiovascular event, MACE

  • Test Drug

    Epanova®

Participate Sites
7Sites

Terminated6Sites

江晨恩
Taipei Veterans General Hospital

賴文德
Kaohsiung Municipal Gangshan Hospital

未分科

2012-02-01 - 2015-02-28

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
7Sites

Terminated7Sites

2008-03-01 - 2010-12-31

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
7Sites

Terminated7Sites

2010-02-01 - 2011-12-31

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Terminated6Sites

2013-01-01 - 2015-06-30

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Terminated6Sites

2008-08-01 - 2012-07-31

Phase II/III

  • Condition/Disease

  • Test Drug

Participate Sites
8Sites

Terminated8Sites

2010-12-01 - 2017-12-31

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
9Sites

Study ended9Sites

2009-12-01 - 2010-09-30

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
3Sites

Terminated3Sites

2010-03-03 - 2010-12-14

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Terminated5Sites

2010-03-03 - 2010-12-31

Phase III

A pan-Asian clinical trial comparing the efficacy and safety of insulin NN1250 and insulin glargin in patients with type 2 diabetes who are currently using oral hypoglycemic drugs. A 26-week, randomized, confirmatory, controlled, open-ended, multi-center, multi-country, clinical trial that achieves the treatment goals, comparing SIBA and insulin glargine injected once a day with oral hypoglycemic drugs for type 2 diabetes The efficacy and safety of patients.

  • Condition/Disease

    Diabetes

  • Test Drug

    Insulin 454 (SIBA) 100 U/ml, 3 mL prefilled pen, solution for injection

Participate Sites
8Sites

Terminated8Sites

1 2 3 4
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB